CXCR4 and small cell lung carcinoma: In SCLC patient samples, AS reduces total CTC counts (<i>p</i> < 0.001), eliminates aggressive phenotypes such as (CK+/CXCR4+/JUNB-) and (CK+/VIM+/GLU+), and increases apoptotic (M30+) CTCs (<i>p</i> = 0.021).